down arrow

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100003YN2
HKD
5.31
0.15 (2.91%)

Feb 16

HKG

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Golden Throat Holdings Group Co., Ltd.
Dawnrays Pharmaceutical Holdings Ltd.
TOT BIOPHARM International Co. Ltd.
Shanghai Henlius Biotech, Inc.
Charmacy Pharmaceutical Co., Ltd.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Clover Biopharmaceuticals Ltd.
Hua Medicine Ltd.
Transcenta Holding Ltd.
Abbisko Cayman Ltd.
Fusen Pharmaceutical Co., Ltd.

Why is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ?

1
Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months
  • High Debt Company with a Debt to Equity ratio (avg) at times
2
Flat results in Dec 23
  • NO KEY NEGATIVE TRIGGERS
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. for you?

Medium Risk, High Return

Absolute
Risk Adjusted
Volatility
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
-100.0%
1.38
42.89%
Hang Seng Hong Kong
18.06%
0.71
25.51%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
1.37%
EBIT Growth (5y)
-14.75%
EBIT to Interest (avg)
2.33
Debt to EBITDA (avg)
47.62
Net Debt to Equity (avg)
0.04
Sales to Capital Employed (avg)
0.34
Tax Ratio
12.05%
Dividend Payout Ratio
56.84%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.05%
ROE (avg)
2.01%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
2
Industry P/E
Price to Book Value
0.10
EV to EBIT
4.50
EV to EBITDA
2.69
EV to Capital Employed
0.13
EV to Sales
0.32
PEG Ratio
0.01
Dividend Yield
NA
ROCE (Latest)
2.99%
ROE (Latest)
4.46%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Icon
Not enough Data to analyse Financial Trend
Icon
Not enough Data to analyse Financial Trend
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."